SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-009885
Filing Date
2023-05-15
Accepted
2023-05-15 16:30:54
Documents
56
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q blph-20230331x10q.htm   iXBRL 10-Q 881513
2 EX-10.1 blph-20230331xex10d1.htm EX-10.1 320401
3 EX-31.1 blph-20230331xex31d1.htm EX-31.1 10009
4 EX-32 blph-20230331xex32.htm EX-32 5977
  Complete submission text file 0001558370-23-009885.txt   4783990

Data Files

Seq Description Document Type Size
5 EX-101.SCH blph-20230331.xsd EX-101.SCH 38773
6 EX-101.CAL blph-20230331_cal.xml EX-101.CAL 22845
7 EX-101.DEF blph-20230331_def.xml EX-101.DEF 170035
8 EX-101.LAB blph-20230331_lab.xml EX-101.LAB 354572
9 EX-101.PRE blph-20230331_pre.xml EX-101.PRE 277790
50 EXTRACTED XBRL INSTANCE DOCUMENT blph-20230331x10q_htm.xml XML 642715
Mailing Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059
Business Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059 908-574-4770
Bellerophon Therapeutics, Inc. (Filer) CIK: 0001600132 (see all company filings)

IRS No.: 473116175 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36845 | Film No.: 23923139
SIC: 2834 Pharmaceutical Preparations